Increase the warfarin dose and recheck INR within 3-7 days
For a patient on 13 mg warfarin daily with a subtherapeutic INR of 1.32, you should increase the weekly warfarin dose by 5-20% and recheck the INR within 3-7 days. This patient is significantly below the therapeutic range (typically 2.0-3.0) and requires dose adjustment rather than watchful waiting 1.
Immediate Management Steps
Dose Adjustment Strategy
- Calculate the weekly dose: 13 mg × 7 = 91 mg/week
- Increase by 10-15%: Add approximately 9-14 mg to the weekly total (new weekly dose: 100-105 mg)
- Redistribute across the week: This translates to approximately 14-15 mg daily, or alternating between 13 mg and 15 mg on different days
- The 2012 ACCP guidelines support dose adjustments for INRs significantly below target rather than continuing the current dose 1
Monitoring Frequency
- Recheck INR in 3-7 days after the dose change 2
- Do not wait the typical 1-2 weeks suggested for INRs only 0.5 units below target 1
- An INR of 1.32 when the target is 2.0-3.0 represents a clinically significant deviation requiring closer monitoring
Critical Considerations
Assess for Contributing Factors
Before adjusting the dose, investigate why the INR is subtherapeutic despite the high daily dose:
- Medication interactions: New medications that induce CYP2C9 or reduce warfarin absorption (rifampin, carbamazepine, phenytoin, St. John's wort) 3
- Dietary changes: Increased vitamin K intake from leafy greens
- Non-adherence: Confirm the patient is actually taking 13 mg daily 4
- Malabsorption: GI conditions affecting warfarin absorption
- Genetic factors: CYP2C9 or VKORC1 variants causing warfarin resistance 2
Bridging Therapy Consideration
Do not routinely bridge with heparin or LMWH for a single subtherapeutic INR in stable patients 1, 5. Research shows that patients with previously stable anticoagulation who experience isolated subtherapeutic INRs have a low absolute risk of thromboembolism (0.4% in 90 days) 5.
However, consider bridging if:
- High thrombotic risk (mechanical mitral valve, recent VTE within 3 months, history of thromboembolism while anticoagulated)
- Multiple consecutive subtherapeutic INRs
- Patient will be subtherapeutic for an extended period
Warfarin Resistance Alert
A daily dose of 13 mg is unusually high (most patients are maintained on 2-10 mg daily) 2. This suggests:
- Possible warfarin resistance: Rare but should be suspected when large doses are needed 2
- Genetic polymorphisms: VKORC1 or CYP2C9 variants
- Drug interactions: Ongoing enzyme inducers
- Non-compliance: Patient not actually taking prescribed doses
If the patient requires >15 mg daily to maintain therapeutic INR after dose escalation, consider:
- Pharmacogenetic testing for CYP2C9 and VKORC1
- Switching to a direct oral anticoagulant (DOAC) if appropriate for the indication
- Referral to an anticoagulation clinic for specialized management 1
Follow-Up Protocol
- Day 0: Increase dose by 10-15% of weekly total
- Day 3-7: Recheck INR
- If INR still <2.0: Increase dose by another 10-15%
- If INR 2.0-3.0: Continue current dose, recheck in 1 week to confirm stability
- Once stable: Extend to monitoring every 1-4 weeks 2
Common Pitfalls to Avoid
- Don't use "watchful waiting" for INRs this far below target—the 2012 ACCP recommendation for continuing the same dose applies only to INRs within 0.5 units of therapeutic range 1
- Don't make excessive dose changes: Increases >20% weekly can lead to overshooting and supratherapeutic INRs
- Don't assume non-compliance without investigation: At 13 mg daily, consider other causes first
- Don't forget to document: The indication for anticoagulation determines acceptable INR ranges (mechanical valves may require 2.5-3.5) 2, 6